<SEC-DOCUMENT>0001564590-20-056121.txt : 20201204
<SEC-HEADER>0001564590-20-056121.hdr.sgml : 20201204
<ACCEPTANCE-DATETIME>20201204060211
ACCESSION NUMBER:		0001564590-20-056121
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20201204
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201204
DATE AS OF CHANGE:		20201204

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PRECISION BIOSCIENCES INC
		CENTRAL INDEX KEY:			0001357874
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38841
		FILM NUMBER:		201368672

	BUSINESS ADDRESS:	
		STREET 1:		302 EAST PETTIGREW STREET
		STREET 2:		SUITE A-100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27701
		BUSINESS PHONE:		919-314-5512

	MAIL ADDRESS:	
		STREET 1:		302 EAST PETTIGREW STREET
		STREET 2:		SUITE A-100
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27701
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>dtil-8k_20201204.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-8k_20201204.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:5pt;border-bottom:Solid 1.5pt;padding-bottom:1pt;margin-bottom:0pt;text-indent:0%;font-size:18pt;">&nbsp;</p>
<p style="text-align:center;margin-top:5pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8-K</p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section&#160;13 or 15(d) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of the Securities Exchange Act of 1934 </p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of report (Date of earliest event reported): December 4, 2020 </p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Precision BioSciences, Inc. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">001-38841</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">20-4206017</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of incorporation)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Commission</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number)</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:33.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">302 East Pettigrew St., Suite A-100, Durham, North Carolina 27701 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices) (Zip Code) </p>
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(919) 314-5512</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code) </p>
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">N/A </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report) </p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section 12(b) of the Act:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.95%;">
<tr>
<td style="width:25.91%;"></td>
<td style="width:25.95%;"></td>
<td style="width:48.09%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, par value $0.000005 per share</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DTIL</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:8pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Global Select Market</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#160;240.12b-2 of this chapter). </font></p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company&#160;&#160;&#9746; </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744; </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 7.01</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Regulation FD Disclosure</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 4, 2020, Precision BioSciences, Inc. (the &#8220;Company&#8221;) issued a press release to announce positive interim clinical results from its Phase 1/2a study of PBCAR0191, its off-the-shelf allogeneic CAR T cell therapy investigational candidate targeting CD19 and the completion of preclinical work for PBCAR19B, its CD19 &#8220;Stealth Cell&#8221; candidate. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 7.01 by reference. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As described in the accompanying press release, the Company will be hosting a conference call at 8:00 a.m., Eastern Time, on December 4, 2020 to review the clinical update. Access to the live webcast and the accompanying presentation materials will be available in the &#8220;Investors &amp; Media&#8221; portion of the Company&#8217;s website at <font style="text-decoration:underline;">https://investor.precisionbiosciences.com</font>. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information contained in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that Section, nor shall it deemed to be incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item 8.01.<font style="margin-left:36pt;"></font>Other Events.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 4, 2020, the Company announced positive interim clinical results from its Phase 1/2a study of PBCAR0191 as a treatment of relapsed/refractory (&#8220;R/R&#8221;) non-Hodgkin lymphoma (&#8220;NHL&#8221;) and R/R B-cell acute lymphoblastic leukemia (&#8220;B-ALL&#8221;).&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of the November 16, 2020 cutoff, 27 patients including 16 patients with R/R NHL and 11 patients with R/R B-ALL had been enrolled and evaluated. For this study, in which patients received either standard lymphodepletion (&#8220;sLD&#8221;) or enhanced lymphodepletion (&#8220;eLD&#8221;), response rates across R/R NHL and R/R B-ALL patient cohorts were as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.23%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">83% objective response rate (&#8220;ORR&#8221;) at day 28 or later for patients across NHL (n=4) and B-ALL (n=2) who received PBCAR0191 when coupled with eLD. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.23%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">At day 28 or later, 75% (3/4) of NHL patients who received PBCAR0191 with eLD achieved a complete response (&#8220;CR&#8221;). Meanwhile, 33% of NHL patients (n=9) across DL2 and DL3 using sLD achieved a CR.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">The longest demonstrated response was &gt; 11 months in a B-ALL patient at DL2. </font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.26%;width:98.63%;">
<tr>
<td style="width:35.07%;"></td>
<td style="width:15.94%;"></td>
<td style="width:15.84%;"></td>
<td style="width:15.92%;"></td>
<td style="width:15.85%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:bold;text-transform:none;font-variant: normal;">Response Rates at Day &#8805;28</p></td>
<td colspan="2" valign="top"  BGCOLOR="#E7E6E6" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">NHL (n=16)</p></td>
<td colspan="2" valign="top"  BGCOLOR="#E7E6E6" style=" border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">B-ALL (n=11)</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:bold;font-style:italic;;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:bold;text-transform:none;font-variant: normal;">ORR</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:bold;text-transform:none;font-variant: normal;">CR</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:bold;text-transform:none;font-variant: normal;">ORR</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:bold;text-transform:none;font-variant: normal;">CR</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:bold;text-transform:none;font-variant: normal;">DL1 (3x105 cells) + sLD</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">67% (2/3)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">0% (0/3)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">-</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:bold;text-transform:none;font-variant: normal;">DL2 (1x106 cells) + sLD</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">67% (2/3)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">33% (1/3)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">33% (1/3)</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">33% (1/3)</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:bold;text-transform:none;font-variant: normal;">DL3 (3x106 cells) + sLD</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">50% (3/6)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">33% (2/6)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">25% (1/4)</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">25% (1/4)</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:bold;text-transform:none;font-variant: normal;">DL4 (2 doses at 3x106 cells) + sLD</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">-</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">-</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">50% (1/2)</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">50% (1/2)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#E7E6E6" style=" border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-style:normal;font-size:10pt;font-family:Times New Roman;font-weight:bold;text-transform:none;font-variant: normal;">Enhanced LD Regimen</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style=" border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">100% (4/4)</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style=" border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">75% (3/4)</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style=" border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">50% (1/2)</p></td>
<td valign="top"  BGCOLOR="#E7E6E6" style=" border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:normal;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">50% (1/2)</p></td>
</tr>
</table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PBCAR0191, which incorporates the Company&#8217;s patented N6 co-stimulatory domain, demonstrated a clear dose dependent increase in peak cell expansion. Compared to sLD, eLD with PBCAR0191 at DL3 resulted in approximately 95-fold increase in peak cell expansion, and approximately 45-fold increase in area under the curve. This was associated with a higher CR rate in NHL (75%). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this dose escalation and dose expansion study, PBCAR0191 had an acceptable safety profile with no cases of graft versus host disease, no cases of Grade &#8805; 3 cytokine release syndrome, and no cases of Grade &#8805; 3<font style="font-size:12pt;"> </font>immune effector cell neurotoxicity. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One NHL patient who was treated with PBCAR0191 and </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LD had previously received nine prior lines of thera</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">py before entering the trial. The patient presented with persistent cytopenias at baseline and a history of infections, including bacterial sepsis. The patient had an episode of sepsis at day 27 which </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">appeared to have </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resolved</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at day 33</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, following which a </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">partial response was achieved at day 34. Unfortunately, t</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he patient died at day 42</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with grade 5 sepsis</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The Company has reported the serious adverse event to the FDA and has reported the patient death.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company plans to enroll additional patients with eLD and plans to present longer term follow-up data on this study by mid-2021. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Company has completed preclinical work, and expects to enter clinical trials in 2021 for PBCAR19B, its CD19 &#8220;Stealth Cell&#8221; candidate, which has shown to delay both T cell and natural killer cell mediated allogeneic rejection in vitro and may improve the persistence of allogeneic CAR T cells.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statements in this Current Report on Form 8-K regarding management&#8217;s future expectations, beliefs, intentions, goals, strategies, plans or prospects are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the expected timing of clinical updates and interim data reports related to PBCAR0191 and the commencement of clinical studies for PBCAR19B. Forward-looking statements may be identified by words such as &#8220;anticipates,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan to,&#8221; &#8220;potential,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors, including, without limitation, the risks referred to under the section &#8220;Risk Factors&#8221; in the Company&#8217;s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, as such factors may be updated from time to time in the Company&#8217;s other filings with the Securities and Exchange Commission (&#8220;SEC&#8221;), which filings are accessible on the SEC&#8217;s website at www.sec.gov and the Investors &amp; Media page of the Company&#8217;s website at https://investor.precisionbiosciences.com. All forward-looking statements speak only as of the date of this Current Report on Form 8-K and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.01.<font style="margin-left:46pt;">Financial Statements and Exhibits</font>. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</p></td>
<td colspan="2" valign="top"  style="width:92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibits </p></td>
</tr>
<tr>
<td colspan="2" valign="middle"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom"  style="width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom"  style="width:7.3%;white-space:nowrap;">
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br />No.</p></td>
<td colspan="2" valign="bottom"  style="width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:90%;white-space:nowrap;">
<p style="border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:6pt;">
<td colspan="2" valign="middle"  style="width:7.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="middle"  style="width:92.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:7.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td colspan="2" valign="bottom"  style="width:2.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="dtil-ex991_120.htm"><font style="text-decoration:underline;">Precision BioSciences Press Release, dated December 4, 2020</font></a></p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:31%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="middle"  style="width:32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="3" valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRECISION BIOSCIENCES, INC.</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  style="width:31%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="2" valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:31%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: December 4, 2020</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:1pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Abid Ansari</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:31%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Abid Ansari</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:31%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dtil-ex991_120.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
dtil-ex991_120.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 99.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:25.15%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gslgrbfrmeum000001.jpg" title="" alt="" style="width:300px;height:74px;"></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;margin-left:1.26%;margin-right:0.99%;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic <font style="margin-left:36pt;"></font>Leukemia (B-ALL)</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:13pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:4.83%;margin-right:0.99%;text-indent:0.04%;;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">Acceptable Tolerability and Safety Profile in 27 Patients with No Graft versus Host Disease (GvHD), No Grade <font style="font-style:normal;font-size:10pt;">&#8805;</font> 3 Cytokine Release Syndrome (CRS), and No Grade <font style="font-style:normal;font-size:10pt;">&#8805;</font> 3 Neurotoxicity (ICANS) </p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:13pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.23%;margin-right:0.99%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">PBCAR0191 Demonstrated Longest Durability of Response to 11 months in B-ALL</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:14pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.26%;margin-right:0.99%;text-indent:0%;;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">PBCAR0191 with Enhanced Lymphodepletion Resulted in Objective Response Rate (ORR) of 83% (5/6) in NHL and B-ALL</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:1.26%;margin-right:0.99%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:bold;font-style:italic;;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_Hlk57899809"></a>-&nbsp;&nbsp;75% (3/4) of NHL Patients had <a name="_Hlk57899809"></a>Complete Response (CR) at &#8805; Day 28</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:center;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Calibri;font-weight:normal;text-transform:none;font-variant: normal;">-&nbsp;&nbsp;Peak CAR T Cell Expansion Increased Approximately 95X in NHL Patients Relative to Standard Lymphodepletion</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.44%;margin-right:0.99%;text-indent:0%;;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">Completed Preclinical Work for PBCAR19B, Next Generation CD19 &#8220;Stealth Cell&#8221; Candidate; Expect to Enter Clinical Trials in 2021</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:13pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:8.39%;margin-right:0.99%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">Company to Host Webcast today at 8:00 a.m. ET </p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:13.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.18%;margin-right:1.79%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DURHAM, N.C., December 4, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS&#174; genome editing platform, today announced positive interim clinical results from its Phase 1/2a study of PBCAR0191, the Company&#8217;s off-the-shelf allogeneic CAR T cell therapy investigational candidate targeting CD19. As of the November 16, 2020 cutoff, 27 patients including 16 patients with aggressive NHL and 11 patients with aggressive B-ALL were enrolled and evaluated.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.17%;margin-right:1.19%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We&#8217;re very proud to share the latest update to our PBCAR0191 study. PBCAR0191, when combined with enhanced lymphodepletion resulted in a high objective response rate of 83% across enrolled NHL and B-ALL patients including those that previously received autologous CAR T therapy or stem cell transplants,&#8221; said Matt Kane, CEO and Co-Founder of Precision BioSciences. &#8220;We believe that this data set represents an important and meaningful step forward in the development of allogeneic CAR T therapies and establishes Precision BioSciences as a leader in the field.&#8221;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:1.17%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:bold;font-style:italic;;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:1.17%;text-indent:0%;;font-weight:normal;font-style:normal;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>&#8220;I am extremely encouraged by what we have observed in this Phase I clinical trial of PBCAR0191. The data answered multiple questions associated with allogeneic cell therapies, including having seen no cases of GvHD. In the enhanced lymphodepletion arm, we observed the highest complete response rate seen to date in R/R aggressive NHL with an allogeneic product,&#8221; said Bijal Shah, M.D., Associate Professor, Malignant Hematology </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:1.17%;;font-weight:normal;font-style:normal;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;"><font style="font-weight:normal;font-style:normal;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">Department</font><font style="font-weight:normal;font-style:normal;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">, </font><font style="font-weight:normal;font-style:normal;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">H. Lee Moffitt Cancer Center and Research Institute</font><font style="font-weight:normal;font-style:normal;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">. &#8220;</font><font style="font-weight:normal;font-style:normal;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">As a result, I am encouraged that the interim data from the PBCAR0191 Phase 1 trial is a meaningful step toward the goal of an off</font><font style="font-weight:normal;font-style:normal;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">-</font><font style="font-weight:normal;font-style:normal;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">the</font><font style="font-weight:normal;font-style:normal;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">-</font><font style="font-weight:normal;font-style:normal;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">shelf CAR T product that could help patients immediately, when they need it most.&#8221;</font></p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:1.17%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:bold;font-style:italic;;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:1.17%;text-indent:0%;;font-style:normal;font-weight:bold;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">Trial Design </p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.16%;margin-right:1.79%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interim data from the Phase 1/2a study of PBCAR0191 includes data from 27 patients: 16 patients with R/R NHL and 11 patients with R/R B-ALL from multiple dose levels. In the NHL cohort, 100% of patients had aggressive lymphomas, 81% had stage III/IV disease, 63% had four or more courses of prior treatment and 25% had prior autologous CAR T. In the B-ALL cohort, 55% of patients had &gt;20% blasts burden at baseline, 82% had 4+ courses of prior treatment and 45% had prior allogeneic stem cell transplant.  </p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.16%;margin-right:1.79%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:1.18%;text-indent:0%;;font-weight:normal;font-style:normal;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">PBCAR0191 treatment at dose level (DL) 1 (3x105 cells), DL2 (1x106 cells), DL3 (3x106 cells) and split dose DL4 (2 doses at 3x106 cells) employed a single standard lymphodepletion (sLD) consisting of fludarabine (30 mg/m2/day for 3 days) plus cyclophosphamide (500 mg/m2/day for 3 days). PBCAR0191 was also dosed in an Enhanced Lymphodepletion Regimen consisting of PBCAR0191 cells at DL3 (n=5) or DL4 (n=1) plus fludarabine (30 mg/m2/day for 4 days) and cyclophosphamide (1000 mg/m2/day for 3 days). </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:1.18%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:bold;font-style:italic;;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:1.18%;text-indent:0%;;font-weight:normal;font-style:normal;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">For this study, in which patients received either sLD or eLD, response rates across R/R NHL and R/R B-ALL patient cohorts were as follows: </p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:1.18%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:bold;font-style:italic;;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.18%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Calibri;">83% ORR at day 28 or later for patients across NHL (n=4) and B-ALL (n=2) who received PBCAR0191 when coupled with enhanced lymphodepletion. </font></p></td>
<td valign="top" style="width:0.79%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.18%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Calibri;">At day 28 or later, 75% (3/4) of NHL patients who received PBCAR0191 with enhanced lymphodepletion achieved a CR. Meanwhile, 33% of NHL patients (n=9) across DL2 and DL3 using standard lymphodepletion achieved a CR.</font></p></td>
<td valign="top" style="width:0.79%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:1.18%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:3.57%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;"><font style="font-family:Calibri;">The longest demonstrated response was &gt; 11 months in a B-ALL patient at DL2. </font></p></td>
<td valign="top" style="width:0.79%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:1.17%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:bold;font-style:italic;;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.17%;width:98.73%;">
<tr>
<td style="width:35.39%;"></td>
<td style="width:15.83%;"></td>
<td style="width:15.83%;"></td>
<td style="width:15.83%;"></td>
<td style="width:15.84%;"></td>
</tr>
<tr>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-style:normal;font-weight:bold;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">Response Rates at Day &#8805;28</p></td>
<td colspan="2" valign="top"  BGCOLOR="#EEECE1" style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">NHL (n=16)</p></td>
<td colspan="2" valign="top"  BGCOLOR="#EEECE1" style=" border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">B-ALL (n=11)</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:bold;font-style:italic;;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">ORR</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">CR</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">ORR</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">CR</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">DL1 (3x105 cells) + sLD</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">67% (2/3)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">0% (0/3)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">-</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">DL2 (1x106 cells) + sLD</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">67% (2/3)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">33% (1/3)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">33% (1/3)</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">33% (1/3)</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">DL3 (3x106 cells) + sLD</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">50% (3/6)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">33% (2/6)</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">25% (1/4)</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">25% (1/4)</p></td>
</tr>
<tr>
<td valign="top"  style=" border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">DL4 (2 doses at 3x106 cells) + sLD</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">-</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">-</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">50% (1/2)</p></td>
<td valign="top"  style=" border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">50% (1/2)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#EEECE1" style=" border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:bold;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">Enhanced LD Regimen</p></td>
<td valign="top"  BGCOLOR="#EEECE1" style=" border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">100% (4/4)</p></td>
<td valign="top"  BGCOLOR="#EEECE1" style=" border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">75% (3/4)</p></td>
<td valign="top"  BGCOLOR="#EEECE1" style=" border-bottom:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">50% (1/2)</p></td>
<td valign="top"  BGCOLOR="#EEECE1" style=" border-bottom:solid 0.75pt #000000; border-right:solid 0.75pt #000000; border-top:solid 0.75pt #000000; border-left:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-weight:normal;font-style:italic;font-family:Calibri;font-size:11pt;text-transform:none;font-variant: normal;">50% (1/2)</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:1.17%;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:bold;font-style:italic;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.18%;margin-right:1.39%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PBCAR0191, which incorporates Precision&#8217;s patented N6 co-stimulatory domain, demonstrated a clear dose dependent increase in peak cell expansion. Compared to sLD, eLD with PBCAR0191 at DL3 resulted in approximately 95-fold increase in peak cell expansion, and approximately 45-fold increase in area under the curve. This was associated with a higher complete response rate in NHL (75%). </p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11.5pt;">&nbsp;</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.17%;margin-right:3.37%;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Safety and Tolerability</font></p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.18%;margin-right:2.18%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this dose escalation and dose expansion study, PBCAR0191 had an acceptable safety profile with no cases of GvHD, no cases of Grade &#8805; 3 CRS, and no cases of Grade &#8805; 3 ICANS. </p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.18%;margin-right:2.18%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.18%;margin-right:2.18%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One NHL patient who </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was treated with PBCAR0191 and </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eLD</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">had </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">previously received </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nine</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> prior lines of therapy</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> before entering the trial. The patient presented with </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">persistent cytopenias at baseline and a history of infections, including </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">bacterial </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sepsis. The patient had an episode of sepsis at day 27 which </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">appeared</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to have </font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">resolved</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at day 33</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, follo</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">wing which a</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> partial response was achieved</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at day 34</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. Unfortunately, the patient died at day 42</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with grade 5 sepsis</font><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11.5pt;">&nbsp;</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.17%;margin-right:3.37%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are rapidly leveraging learnings from this study and enrolling more patients into our enhance lymphodepletion regimen. In parallel, we continue to evaluate higher cell doses, repeat dosing and other novel methods to further optimize our dosing strategy,&#8221; said Chris Heery, Chief Medical Officer at Precision BioSciences. &#8220;We also plan to pursue clinical development of PBCAR19B, our CD19 Stealth Cell candidate, which has shown to delay both T cell and natural killer cell mediated allogeneic rejection in vitro. We believe this is likely to result in improved persistence of allogeneic CAR T cells. We expect to move PBCAR19B into the clinic in 2021.&#8221;</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.17%;margin-right:3.37%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:1.18%;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Company-Hosted Conference Call and Web Cast Information</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.18%;margin-right:1.39%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Precision will host a conference call and webcast today, December 4, 2020 at 8:00 a.m. ET to discuss the updated interim clinical data and the learnings for PBCAR0191 from both the NHL and B-ALL cohorts of this trial, as well as PBCAR19B. The dial-in conference call numbers for domestic and international callers are (866) 996-7202 and (270) 215-9609, respectively. The conference ID number for the call is 6368255. Participants may access the live webcast and the accompanying presentation materials on Precision's website https://investor.precisionbiosciences.com/events-and-presentations in the Investors and Media section under Events and Presentations. An archived replay of the webcast will be available on Precision's website.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.19%;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Precision BioSciences, Inc.</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.18%;margin-right:1.19%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS&#174; genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company&#8217;s pipeline consists of multiple &#8220;off-the-shelf&#8221; CAR T immunotherapy clinical candidates and several <font style="font-style:italic;">in vivo </font>gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit <font style="text-decoration:underline;color:#0562C1;">www.precisionbiosciences.com</font>.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:10.5pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:1.19%;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About PBCAR0191</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.18%;margin-right:1.59%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PBCAR0191 is an investigational allogeneic chimeric antigen receptor T cell therapy (CAR T) in Phase 1/2a trials for the treatment of patients with R/R NHL and R/R B-ALL. PBCAR0191 was designed using Precision BioSciences novel and proprietary ARCUS&#174; genome editing platform. It has been granted Fast Track Designation by the FDA for B-ALL. Precision also holds Orphan Drug Designation from the FDA for this program in mantle cell lymphoma, an aggressive subtype of NHL. PBCAR0191 is being developed in collaboration with Servier. </p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.18%;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">About Precision&#8217;s Collaboration with Servier</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.17%;margin-right:2.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>Under the terms of the agreement with Servier, Precision is solely responsible for early-stage research activities as well as PBCAR0191 Phase 1/2a clinical trial execution and clinical supply. Servier has the exclusive right to opt in for late-stage development and commercialization, and Precision has the right to </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.17%;margin-right:2.98%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and co-promotion option in the United States.</font></p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.17%;margin-right:2.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.17%;margin-right:2.98%;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.17%;margin-right:2.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the expected timing of clinical updates and interim data reports related to PBCAR0191 and the commencement of clinical studies for PBCAR19B. In some cases, you can identify forward-looking statements by terms such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;expect,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;mission,&#8221; &#8220;goal,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;project,&#8221; &#8220;predict,&#8221; &#8220;contemplate,&#8221; &#8220;potential,&#8221; or the negative thereof and similar words and expressions.</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.17%;margin-right:2.98%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.17%;margin-right:2.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>Forward-looking statements are based on management&#8217;s current expectations, beliefs and assumptions and on information currently available to us. Such statements are subject to a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to become profitable; our ability to procure sufficient funding and requirements under our current debt instruments and effects of restrictions thereunder; risks associated with raising additional capital; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities, preclinical or greenhouse studies and clinical or field trials; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, biotechnology and agricultural biotechnology fields; our or our collaborators&#8217; ability to identify, develop and commercialize product candidates; pending and potential liability lawsuits and penalties against us or our collaborators related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators&#8217; development of product candidates; our or our collaborators&#8217; ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; our or our collaborators&#8217; ability to advance product candidates into, and successfully design, implement and complete, clinical or field trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; our ability to obtain an adequate supply of T cells from qualified donors; our ability to achieve our anticipated operating efficiencies at our manufacturing facility; delays or difficulties in our and our collaborators&#8217; ability to enroll patients; changes in interim &#8220;top-line&#8221; and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; the rate and degree of market acceptance of any of our product candidates; the success of our existing collaboration agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; our ability to effectively manage the </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.17%;margin-right:2.98%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">growth of our operations; our ability to attract, retain, and motivate key executives and personnel; market and economic conditions; effects of system failures and security breaches; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events effects of the outbreak of COVID-19, or any pandemic, epidemic or outbreak of an infectious disease; insurance expenses and exposure to uninsured liabilities; effects of tax rules; risks related to ownership of our common stock and other important factors discussed under the caption &#8220;Risk Factors&#8221; in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC&#8217;s website at www.sec.gov and the Investors &amp; Media page of our website at investor.precisionbiosciences.com.</font></p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.17%;margin-right:2.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-top:1pt;margin-bottom:0pt;margin-left:1.17%;margin-right:2.98%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:13pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:1.17%;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Investor Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.17%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alex Kelly</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:1.17%;margin-right:60.52%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Corporate Affairs Officer <font style="text-decoration:underline;color:#0562C1;">Alex.Kelly@precisionbiosciences.com</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:8.5pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:1.19%;text-indent:0%;font-weight:bold;font-family:Calibri;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">Media Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.19%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maurissa Messier</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.19%;margin-right:53.37%;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Director, Corporate Communications <font style="text-decoration:underline;color:#0562C1;">Maurissa.Messier@precisionbiosciences.com</font></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gslgrbfrmeum000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gslgrbfrmeum000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !+ 2T# 2(  A$! Q$!_\0
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MYM*IR2YCTZM/GCRF!;?#7PE:R!UTB-R#D>:[./R)KJ(HHX(EBAC6.-!A408
M'L*?142G*7Q.Y481C\*L>8_&5%DL]!1U#(U[A@>XP*Z*Y^&_A2XLYH$TB"%I
M$*B5,[D/J.>HKH-0TG3]5$0O[.*Y$+[X_,7.UO45<K3VS4(QB[6,_8ISE*2O
M<\R\ :S=>']7F\#ZVP6: DV,IX$B=<#^8_$=JZ#XF?\ )/=6_P!Q/_0UK>O-
M$TS4+N"[N[&":X@_U4KK\R<YX/UJQ>65MJ%I):WD"3V\@P\;C(:FZD744[>H
M*G)4W"_H</X1\;^&K'PAI-K=:Q;Q3Q6R(Z-G*D#ITK9_X6%X2_Z#MK^O^%3_
M /"#^%_^@#8_]^A1_P (/X7_ .@#8_\ ?H42=%N^OX"BJR5M/Q+&NZ19^*O#
MDUC(X,%U&&CE7G:>JL/TKS_P[XNN_ C+X;\702I!"=MK?(I92G8>X^G(Z$5Z
MK'&D,211J%1%"JHZ #H*BN[*UOX#!>6\4\1ZI*@8?K4PJ))QDKHJ=-M\T79F
M"WQ!\)K$9#KMH0!G 8EORZUSMKXWUCQ9XFMK?PO:E-)@?-U=W,?RN.X'I[#K
MGVKI%\!>%%DWC0K/<#G[G'Y=*WX+>&UA6&WACBB7HD:A0/P%5S4H_"KOS)Y:
MLOB=EY'&?%K_ ))]>?\ 72+_ -#%:ND->K\/K%M-6)KT:?&85E^Z6V# -;-_
MI]IJ=HUK?6\=Q;L06CD7(..E2P0Q6T$<$*+'%&H5$48"@= *GG7(H^=RN1\[
MEY6.!\,_$VSE@:Q\3N-,U:W)243*41_<>GT-4_B#XYT?4/#LVB:1.-1OK[;$
MJ6X+!>0<Y]>. *[O4_#VCZT5.I:;;7++T:1!N'X]:9IGA?0]&E,NGZ7;6\I_
MC5/F_,\U:G24N>SOVZ$.%5QY+JW?J0>&]-FT?P78Z?<?ZZ"UVR#T;&2/PS7(
M?!?_ ) .J_\ 7^?_ $%:]+(# @C(/!%5-.TG3])B>+3[2*VCD;>ZQ+@%O6H]
MI[LD^I?L_>BUT.'\>>&M3AUBU\7>'5+:C: "> #F5![=^,@CT^E7=%^*7AW4
M;<"^N/[-NUXEAN00 >^&Z?R-=O63J7AC0]7D\R_TJUGD_OM&-WYCFJ52,HJ-
M1;=1.G*,G*F]^A@ZQ\4?#6FVY-M>#4+@\1PVPW;C[GH*RO!/A[5=5\13>,_$
M<7E7,HQ:6Q&#$N, X/3C@=^2:['3O"N@:3+YMCI-I#)V<1@L/Q-;%#J1C%JF
MM^HE3E*2=1[=$<%\8?\ D09?^OB+^==CI/\ R!K'_KWC_P#013M0TVRU6U-K
M?VT=S 2&,<BY&1TJPB+%&L:*%10%4#H *AS3@HEJ#4W+N<]XQ\)6WBO2?)8^
M3>P_/:W ZQO_ (&O// 2:FFO>)%UA674!)")LC&3\_/OGKFO9JJOIUG)<O<O
M;1F9U"L^.6 S@'Z9/YU<*SC!P>Q,Z*E-36YXI\6?"\D?C"SOH$_<ZHRQD@=)
M>!^HP?SKVRTMHM.TZ&VC 6&WB"* .@48J+5=)M=8M4@NDR(Y4FC8=5=3D$?Y
M[U;E3S(73^\I'YTJE5SA&+Z!"DH3E)=3Y+U_4)-5U^_OI6W-/.S9]L\#\L5G
M5/>PM;7]Q XPT<C(0?4'%05[B22T/#;;>I;TJ_DTO5K2_CY>WE60#UP<XKU_
MQMX67Q]96OBGPTZ7$K1!)H-P#-CM[,.A!]J\5K3T?Q!JV@3&72[Z:V9OO!#\
MK?4'@UE4IMM2B]4:TZB2<9+1GKFB_"70-4TN*YN(]6LK@_++!,P!1AUQ\O(]
M#6KK_AD>$?AEJUCH$,LYFRTS.P+[#@,>!SA1T^M<5X5^+&N/XCLH=8NDEL97
M$4G[M5*YX#9 ['^M>\$!E*L 5(P0>]>=6E5IS7.[K<]&C&E4B^16>Q\BZ3IE
MQK&K6NG6RYFN) B^V>I^@ZU]9:=8Q:9IMM8P#$5O$L:_0#%<KX8^'EAX;\1Z
MAJT9#^<Q%JF/]0A^\/KGCZ5V=+%5U5:4=D/"T'23<MV%<=JMQK-]XZ&C6&KM
MI]NNG_:6*VZ2$MOV_P 5=C7!ZIH]GK7Q1%O?)(\::3O4)*R'/FXZJ0:QI6N[
M]C:K>RMW-/0M0U2#Q/>>']3O([_RK9;F.Y6(1L 6QM<#C/<5TER[1VDSJ<,J
M,0??%<3;6-MX7\>V&GZ-(YAU**1KVV>0R%-@&R3)R1U(ZXKM+W_CQN/^N3?R
MHJ)7374*;=FGT,KP=J-UJWA'3;^]D$EQ-%ND8*!DY/84WQ+KMQI?V.QTZ!+C
M5;]S';1N<(H RSM_L@57^'G_ "(&C_\ 7'_V8U4\42+I'B[0M>N>-/C66TGE
MQQ"7QM8^@R,9I\J]JUZBYG[)/T)6T7Q>D7GQ^*8Y+H<^1)9(("?3CY@/?-:7
MAK73KEE-Y\'V:_M)3;W<&<[)!Z'N#U!K4DO+:*T-U)<1+;A=QE+C;CUSTKEO
M!.Z^OM>UU$9+34;M3;;AC>B*%WX]"12OS1;:V';EDDGN7O&.L76BZ+'+9O%%
M-/<Q6PGE&4@#G!<CT%/TFQU^QU ?:]8BU/3WC)+20B.5'[8V\%3[U<UBYTE8
MHK#5VA\J^8PI',/ED.,X]*Y9K5O!GB/1[/3+V:33]2F,#:=,YD\KY2=\9/(
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&&][:G__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
